Clinical context
Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.
What was studied
This systematic review evaluated Hill-RBF 3.0 against traditional and newer IOL calculation formulas. EMBASE, MEDLINE, CINAHL and Web of Science were searched on 17 March 2025. Of 130 records screened, 31 studies entered the qualitative review and 28 the quantitative meta-analysis; outcomes included mean absolute error and the probability of landing within ±0.25, ±0.50 and ±1.00 D.
How the evidence was produced
A meta-analysis combines several studies and can increase the precision of an overall estimate. Its conclusion still depends on the quality of the component studies, comparability of interventions and endpoints, statistical heterogeneity and publication bias. The pooled effect should be read with its confidence interval, sensitivity analyses and the reasons results differed across studies.
How to interpret the result
The clearest advantage for Hill-RBF 3.0 was over several traditional formulas. Performance was more often comparable when it was assessed against other contemporary methods, so the review does not establish absolute superiority over Kane, Barrett Universal II, EVO or Pearl-DGS. Practical relevance depends on the size of the refractive gain, appropriate constant optimization and the characteristics of the individual eye.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.
Limitations
The meta-analysis combined different populations, axial-length ranges, biometers and IOL models. A standardized difference in mean error supports pooling but is less intuitive for an individual prediction in diopters. Small odds ratios may reach statistical significance without representing a large clinical effect. Published comparisons can also lag behind updates to online formulas.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.